is RETIRED
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wish to thank all those who shared their thoughts and advice
about investing in Biophan. For those who can now say "I told
you so!", please set a good example as I am confident that I
will be one of those who will be saying that next year. Of course I was thinking that at this time last year. But were we ready then? I do not think it was our time. Now I own a lot more BIPH shares than I did then. Despite the fact that my shares are worth a lot less money now, I believe the Company is more valuable now than it was a year ago. Of course my "IMHO" has to stress the "H".
GOOD LUCK AND BEST WISHES FOR THE NEW YEAR.
ALMI made the Pinksheet Biggest Net Losers today. The volume was 203,430 shares. The CLOSE was at 75 cents a share.
BIPH hit a new 52 week low at 5 cents a share. The market now
values the Company at $4,841,500.
Old news re VAD:
NanoDynamics Inc. Receives $100,000 Contract from National Institutes of Health For Ventricular ...
Dec 6, 2007, 12:00pm
Joint Initiative with University of Pittsburgh Will Investigate Capabilities of Nanosilver in Microbial Growth Inhibition
BUFFALO, N.Y., December 6, 2007 – NanoDynamics Inc. announced that its subsidiary ND Life Sciences received a six-month, $100,000 Phase I SBIR contract from the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI). Based in Pittsburgh, ND Life Sciences develops nanomaterials and nano-enabled technologies specifically for applications in biotechnology and medicine. The contract, which took effect this September, will support NanoDynamics’ joint efforts with the University of Pittsburgh to address the critical issue of infection associated with ventricular assist devices (VADs), and specifically the drivelines of these devices.
The University of Pittsburgh and ND Life Sciences will use this SBIR funding to speed the development of nanotechnology-based infection-resistant driveline coatings. This work will also be directly applicable to other widely used medical device implants such as shunts and catheters.
“With cardiovascular disease as the leading cause of death in the U.S., it has been estimated that between 15,000 and 50,000 patients, including children, could benefit annually from mechanical circulatory support devices including total artificial heart implants and VADs,” said Dr. Harvey Borovetz, professor and chair, department of bioengineering at the University of Pittsburgh. “To achieve improved clinical outcomes with these devices, a viable and proven antimicrobial solution is needed for entry point components such as drivelines, as entry point areas are often a locus for patient infection.”
“The majority of intracorporeal device infections are caused by biofilm-forming bacteria and fungi, which severely limits the antibiotic arsenal available to treat them,” said Dr. Alan Russell, director of McGowan Institute of Regenerative Medicine and university professor of surgery at the University of Pittsburgh. “With limited success in the reduction of device-associated infections, the most often-used therapy to treat an infection is outright removal of the device.”
Work funded by the SBIR contract will investigate the ability of coatings with anti-infective nanosilver to increase biocompatibility and inhibit bacteria adhesion on the surfaces of indwelling medical devices.
“The antimicrobial activity of silver in its ionic form has been well-known for centuries,” explained Dr. Alan Rae, vice president of NanoDynamics’ strategic business unit, ND Innovations. “In fact, of all metal ions, silver exhibits the highest toxicity for microorganisms without being a threat to healthy mammalian cells. In addition, nano-scale silver has uniform distribution capabilities along with a large surface area to ensure the release of effective concentrations of silver to combat bacteria.”
The work funded by this initial Phase I contract is expected to progress from bench testing to eventual in vivo trials.
About NanoDynamics
Headquartered in Buffalo, N.Y., NanoDynamics, Inc. develops and commercializes technologies, materials and products ....
Safe Harbor.......
"Amazing ALMI goes pink Monday"
Today may be the last day that Atlas Mining Company trades on
the OTC Bulletin Board (OTCBB). I doubt that management is prepared to present financial statements to the SEC on this last day for filing. Why? They had the cash to pay a CPA firm to prepare the books.
We should have received a letter of explanation from CEO Bill Jacobson in MHO.
So why is PG not a buyer now that they have validated
NaturalNano's Controlled Release Technology?
Is the pricing out of line with benefits?
Biophan Announces Appointment of James Goldberg as Interim President for Myotech
PITTSFORD, NY--(MARKET WIRE)--Dec 18, 2007 -- Biophan Technologies, Inc. (OTC BB:BIPH.OB - News), a developer of next-generation biomedical technology, today announced the appointment of James Goldberg as interim President of Myotech, LLC, effective immediately. Myotech is a majority-owned subsidiary of Biophan Technologies, Inc............
John Lanzafame, Biophan Chief Executive Officer, stated, "As the Myotech Circulatory Support System (CSS) moves toward clinical trials and ultimately market entry, Jim Goldberg's vast experience in running early- and mid-stage healthcare companies will be an invaluable asset."
Mr. Goldberg commented, "This is a very pivotal period in the Myotech's development, and I am honored to have an opportunity to contribute to its growth and development as the company moves closer to commercialization."
The Myotech Circulatory Support System (CSS) consists of an external drive unit and flexible polymer cup that slips over the heart and provides the energy that enables the heart to restore normal blood flow. It can be installed in approximately three minutes with a small incision to provide immediate, life-saving support in emergency situations. Since it has no contact with circulating blood, the Myotech CSS also promises to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.
I think the time has come at PPS of $0.06. I wish I had paid attention to what "MommaSaid" and held off until now, but I am buying more BIPH here. Do you still think that this is a purchase point.
Biophan (BIPH) has now hit a new 52 week low at $0.056 a share.
The ALMIE Short Interest for November 27, 2007 was 435,853 shares. That was about a 22% drop from the prior report. Based on the Average Daily Share Volume (ADSV) of 103,551, the Days to Cover was 5.
On 11/27/2007 ALMIE closed at $066. The PPS has been as low as $0.52 since that date. It Closed at $0.80 on 12/14/2007.
A reminder - from the Biophan 10K for the fiscal year ended February 28, 2007 : "It is anticipated that the Gen-1 MYO-VAD will enter into clinical studies in fiscal year 2008. The clinical study is planned to include fifty to sixty patients at 6 to 10 centers. It is anticipated that it will take approximately six months to complete the clinical study. The MYO-VAD is targeted to be marketed and distributed by entering into a strategic relationship with a major medical device company.;
Proof of concept was demonstrated. The question is if Biophan has retained its rights under the Joint Research Agreement between Nanosolutions, LLC and NaturalNano, Inc. dated as of May 25, 2005.
Controlled Release of drugs is believed to be a very important area in the future of medical care. I suspect that Biophan has real value to sell if Nanosolutions, LLC still retains its rights under that Agreement.
NaturalNano has purchased Halloysite from New Zealand source.
See SEC form SB-2/A NaturalNano , Inc.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5333493
Filed on: December 13, 2007
See page 22
"During the three months ended September 30, 2007, the Company purchased a supply of 15 tons of halloysite nanotubes from a mine in New Zealand. A portion of these halloysite nanotubes have been used to produce Pleximer which is available for sale. As of September 30, 2007, the $21,302 cost to purchase, ship, store halloysite nanotubes and produce Pleximer being held in inventory is reflected on the Company’s balance sheet as a current asset. The Company expects that such inventory will be fully utilized on or before September 30, 2008."
NaturalNano has purchased Halloysite from New Zealand source.
See SEC form SB-2/A NaturalNano , Inc.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5333493
Filed on: December 13, 2007
Management of Atlas Mining Company has to bring the Company's
reports current by December 23, 2007.
This is from the SEC web page:
""E" Added To Stock Ticker Symbol
When a company that trades on the OTC Bulletin Board (OTCBB) becomes delinquent in its reporting obligations with the SEC (for example, it submits a required filing late or in an incomplete form), the letter “E” will be appended at the end of the company’s stock ticker symbol. After the “E” is added, the company is given 30 calendar days (60 calendar days for most foreign companies and domestic banks), known as the “grace period,” to become current in its reports. If the company files complete required reports during the grace period, the “E” will be removed. If the company fails to correct its deficiency, the company’s stock symbol will be removed from trading on the OTCBB."
The purchase by the IBS funds managed by David A Taft of an additional 262,500 ALMI shares on or about 12/04/2007 gives me hope that there will be another turnaround in the fortunes of Atlas Mining Company. The purchase represented the investment of an additional $157,159 in the Company. IBS funds now own 9,689,082 ALMI shares. That number is about 18% of the 54,173,594 shares outstanding.
Why should not this report be important news for BIPH stockholders: "Leading Consumer Products Manufacturer Validates NNAN’s Controlled Release"?
It is my belief that Biophan still holds its rights to
NaturalNano's halloysite controlled release system. Those
rights pertained to all medical uses of drug delivery applications.
BIPH was down almost 15% today to $0.071 on 1.63 million share volume. There was no news to account for the volume.
Tomorrow is the last day of Biophan's 3rd quarter.
It has benn almost a year since Biophan announced successful animal testing of the Myovad CSS device. The web site says that the device is ready for commercialization. A lot of money has been spent on the development of this product candidate that seemed to have a great deal of promise.
What can the matter be?
Targeted Genetics restarts trial after woman's death
By Ángel González
Seattle Times business reporter
11//26/2007 Seattletimes.com
PR of 11/19/2007 in part: (see NaturalNano.com for full text)
"NaturalNano said it is currently developing halloysite nanotubes (HNT(TM) sources and potential partnerships in the western United States as part of the Company’s ongoing focus on industry partnerships and joint venture sourcing and technology development. While undergoing the development process, NaturalNano said it continues to have access to reserves of HNT to meet customer demand and to continue laboratory-scale testing of additional Pleximer products. NaturalNano has purchased and is warehousing a six month supply of HNT based on current projections, and will continue to add to the supply throughout 2008. NaturalNano said it expects to introduce several new Pleximer products in the first half of 2008, with extended release applications coming online later next year."
PR of 11/19/2007 in part: (see NaturalNano.com for full text)
"NaturalNano said it is currently developing halloysite nanotubes (HNT(TM) sources and potential partnerships in the western United States as part of the Company’s ongoing focus on industry partnerships and joint venture sourcing and technology development. While undergoing the development process, NaturalNano said it continues to have access to reserves of HNT to meet customer demand and to continue laboratory-scale testing of additional Pleximer products. NaturalNano has purchased and is warehousing a six month supply of HNT based on current projections, and will continue to add to the supply throughout 2008. NaturalNano said it expects to introduce several new Pleximer products in the first half of 2008, with extended release applications coming online later next year."
NaturalNano Ramps up Worldwide Exploration of Additional Halloysite Nanotube (HNT(TM)) Deposits - Marketwire Mon, Nov 19, 2007
SEC form NT-10-Q was filed on 11/15/2007. It reads in part:
PART III – NARRATIVE
As previously announces and as described most recently in the current report on Form 8-K of Atlas Mining Company (the “Company”) dated October 9, 2007, the Company has determined that it will need to restate its historical financial statements to reflect funds received in 2004 as a deposit for the sale of halloysite clay, instead of revenues, as previously recorded. In addition, the Company is currently reviewing prior period records specific to historical equity transactions, accounting for fixed asset acquisition, and long-term liabilities.
Due to the pending restatement, the Company is unable to file the Form 10-Q on or before the prescribed due date of November 14, 2007, or on or before the fifth calendar day following such filing date as prescribed in Rule 12b-25. The Company intends to file its Form 10-Q as soon as practicable after the completion of the restatement.
ALMI has moved up over 18% today on 361.51 k Volume.
Can anyone venture a guess as to what is happening?
For a company with a market cap of under $10,000,000, the clearing of $1,050,000 of debt would seem to me to be a more significant event than the market does.
The law suits with SBI must have been cash burning ventures seeking perhaps uncollectible judgements.
Biophan IMO should now be a very attractive firm for a large
medical equipment company to team up with in a joint venture
to take Myovad to human trials.
I-MINERALS last traded at $1.25. That is up about 25% for the day. However the BID is $1.00 and the ASK is $1.10. This is still up from about $0.80 the last day of October when it was at a new High. Only 18,250 shares have traded today. That is just above average.
NaturalNano Launches Development of Extended Release Applications
7:00 AM EST November 6, 2007
ROCHESTER, NY -- (MARKET WIRE) -- 11/06/07 -- NaturalNano, Inc. (OTCBB: NNAN) (FWB: N3N) (www.naturalnano.com), a developer of advanced nanomaterials and additive technologies, today announced the Company is advancing to the next stage in its commercialization strategy, developing extended release applications for its family of Pleximer(TM) products. Recently, NaturalNano announced the commercialization of its first product within the Pleximer suite, a nylon-based additive known as Pleximer-N?. Additional Pleximer products will be introduced in early 2008, with extended release applications coming in the second half of 2008.
Pleximer is NaturalNano's proprietary patented, turn-key nanocomposite concentrate that, when added to a composite polymer material, produces stronger, lighter and less expensive products. NaturalNano reported it is moving to the next phase of laboratory-scale research and testing focused on filling the Halloysite Nanotubes (HNT?) with selected additives to create a slow, extended release. By filling the naturally occurring hollow tubes, NaturalNano can further customize Pleximer to meet manufacturers' needs.
"We see commercializing Pleximer with extended release capabilities as not only the next step in expanding our product offerings, but as the next evolutionary stage in the development of nanocomposites," said Cathy Fleischer, President and Chief Technical Officer of NaturalNano. "By mastering the ability to affect the release of various chemicals, nanocomposites become a highly specialized material with competitive advantages for commercial and consumer products."
NaturalNano's research team is currently working to fill the HNTs with fragrances that could be released slowly over time, in order to create coatings with a wide variety of uses. The Company noted that the potential exists for these coatings to enhance a diverse range of products in the $107 billion fabric industry, where researchers could add antimicrobial compounds to athletic clothing or extend the life of the popular "new car" smell. Additionally, NaturalNano believes that efforts in the $25 billion furniture industry could include adding such compounds as flame retardants to furniture which would release only when under extreme heat.
NaturalNano maintains one of the most significant intellectual property portfolios in extended release research in the nanocomposite industry. This extensive portfolio and expertise allowed the Company to acquire an exclusive license agreement with the U.S. Naval Research Laboratory for 10 patents in controlled release nanomaterials covering many industries.
"This expertise provides us with the opportunity to become not only the product pioneer in this space, but to also be the toll booth for other nanocomposite developers targeting the extended release market," Fleischer concluded. "While fabrics and furniture are the first step in our development of controlled release applications, we see a number of other opportunities on the horizon, including applications in the cosmetics and agri-chemical industries. By working to enhance the properties of commonly used products such as sun-block or anti-aging cosmetics we believe we are positioned to continue to lead innovation in nanomaterials." ............
RedChip conference presentation is to take place at 6:45 am PDT on Nov. 3. It is to last for 25 minutes. Go to the RedChip site and register to watch.
I would hope that NaturalNano would have a more exciting story to tell at the conference than what they have today.
Maybe we will hear something before the end of the week about
a sale of product or a money bag joint venture partner.
Otherwise why spend the money to present at the conference.
John Lanzafame, President and CEO of Biophan had been President of Biophan's Nanolution drug delivery division. That division is not mentioned in the PR regarding Biophan's plans.
See Post #1416 for info re a patent would be of interest to NaturalNano.
Biophan Outlines Commercialization Strategy - Marketwire
Tue, Oct 30, 2007 7:30 AM
This PR says nothing IMO and the market seems to agree with me.
Maybe it is a hint that Biophan will sell its division to NaturalNano as soon as NaturalNano is in a position to buy that
division.
It may be that the two factors that caused the tumbling down of the Biophan market cap had nothing to do with Mike Weiner.
The first was the crash of Boston Scientific. Its PPS was about $45 in mid 2004. It has now been about $15 following a steady decline.
Second was the failure of SBI Brightline to live up to its financing arrangement with Biophan. That is a subject in litigation.
As I understand the offering, the "lenders" would have to convert their notes - $5,287,756 in face amount - for them to obtain 35,251,707 of the shares being registered. The company would not receive any proceeds from the sale of the BIPH shares, but the conversion would reduce the liabilities of the company by $5,287,756 which figurers out to be $0.15 a share.
The other shares being registered represent payment in shares of interest on the notes.
What is happening to NNAN today. It is down over 10%.
Biophan (BIPH) now has a Market Cap of only $13.5 million. That is based on a PPS of $0.135 and 96.83 million shares outstanding.
Would it be reasonable to expect a FDA Fast Tract for the Myotech CSS if the early human trials go well?
Is the company seeking a major player to joint venture the
human trials?
NaturalNano is to be a presenter at Red Chip conference:
ORLANDO, Fla., Oct. 26, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced that the CEOs and executive teams of twenty-one small-cap companies will present at RedChip's Small-Cap Investor Conference in Orlando, Florida, November 3, 2007. The Conference will feature RedChip TV(tm) interviews, networking events, and financial presentations before hundreds of investment bankers, fund managers, institutional and accredited investors, research analysts, and high net worth individuals.
Investors all over the world will be able to see and hear presenters at the conference in real time at http://www.redchip.com.
The ALMI Short interest for October 16, 2007 was 738,040. That was about a 1% drop from the prior report. Based on the Average Daily Share Volume (ADSV) of 962.416, the Days to Cover was 1.
On 10/16 the ALMI PPS was .95 at the Open and at .98 at the Close. The ADSV for this report is misleading as it is greatly impacted by the 6,418,299 shares traded 10/9/07, the
day of the "new management" PR.
NaturalNano Introduces Next Generation Additive, Pleximer-N(TM) - Marketwire Thu, Oct 25, 2007
Might be reading tea leaves, but the timing was right to pull the Dragon crew off and redeploy them at the contract job down the road in Utah. The positive is the Atlas Mining cash flow.
We should know in a day or two if our major stockholder was buying again in the 75 cent range today. I sure hope that the Turnaround Fund manager knows what he is doing buying more ALMI.